An unconventional gatekeeper mutation sensitizes inositol hexakisphosphate kinases to an allosteric inhibitor
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Germany
- Institut für Chemie, Humboldt-Universität zu Berlin, Germany
- Max‐Delbrück‐Center for Molecular Medicine in the Helmholtz Association (MDC), Germany
Figures
Figure 1
The inositol pyrophosphate pathway is a therapeutically relevant target for small molecule inhibitors.
(a) Simplified inositol pyrophosphate metabolism with a focus on kinases. PPIP5K: inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase. *PP-InsP dephosphorylation is catalyzed by …
Figure 2 with 4 supplements
An unusual valine gatekeeper mutant retains catalytic activity.
(a) Sequence alignment of InsP kinases to identify the gatekeeper position of human inositol hexakisphosphate kinases (IP6Ks). The gatekeeper residue is highlighted in orange. (b) Kinase reaction of …
Figure 2—figure supplement 1
Kinase reaction of inositol hexakisphosphate kinases (IP6Ks) using fully 13C-labeled InsP6 as a substrate.
The conversion to 5PP-InsP5 was followed by the established spin-echo difference NMR method (Harmel et al., 2019). The peaks corresponding to substrate and product are framed with solid or dashed …
Figure 2—figure supplement 2
Catalytic activities of IP6K2 wild-type (WT) and gatekeeper mutants as indicated by the apparent turnover number.
All samples were measured in independent triplicates and error bars represent standard deviation.
Figure 2—figure supplement 3
Screening of established electrophile-sensitive kinase inhibitors at 10 µM concentration against IP6K1L210C using the NMR assay.
All compounds were measured in independent triplicates and error bars represent standard deviation.
Figure 2—figure supplement 4
Chemical structures of established analog-sensitive kinase inhibitors screened against IP6K1L210V.
Figure 3 with 2 supplements
High-throughput screening provides gatekeeper mutant-selective hit compound.
(a) ATP synthase reaction used for the high-throughput screen. The generation of ATP was monitored using a luminescence-based Kinase-Glo assay. (b) Reduction of putative hits by applying specific …
Figure 3—figure supplement 1
Optimization of assay conditions for high-throughput screening.
(a, b) Serial dilution of substrate and protein in single measurements to determine suitable concentrations for the high-throughput screen using the Kinase-Glo assay. (c) Substrate conversion at …
Figure 3—figure supplement 2
Z' plate measurement and Bland-Altman plot indicate high assay quality.
(a) Z′-plate with positive and negative controls to assess the assay quality and high-throughput screen viability. Dashed lines indicate the ± 3*standard deviation values. (b) Bland–Altman plot of …
Figure 4 with 3 supplements
FMP-201300 appears to have very specific interactions with the kinase.
(a) IC50 curves of FMP-201300 against IP6K1wt and IP6K1L210V. (b) IC50 curves of FMP-201300 against IP6K2wt and IP6K2L210V. 100% activity corresponds to the DMSO control and 0% indicates no …
Figure 4—figure supplement 1
Characterization of the interaction between FMP-201300 and EhIP6KA.
(a) IC50 curves of FMP-201300 against IP6KAwt and IP6KAM85V. (b) Lineweaver–Burk plot of FMP-201300 against IP6KAwt. All points were measured in independent triplicates and error bars represent …
-
Figure 4—figure supplement 1—source data 1
Data collection and structure refinement statistics of EhIP6KAM85V crystallization.
- https://cdn.elifesciences.org/articles/88982/elife-88982-fig4-figsupp1-data1-v1.docx
Figure 4—figure supplement 2
Established pan-IP6K inhibitor TNP displays ATP-competitive mechanism and no selectivity towards the valine gatekeeper mutant.
(a) Lineweaver–Burk plot of TNP against IP6K1wt. (b) IC50 curves of TNP against IP6K1wt and IP6K1L210V. All points were measured in independent triplicates and error bars represent standard deviation.
Figure 4—figure supplement 3
Reverse transcription quantitative PCR analysis to measure 45S pre-rRNA transcript levels using two different primer sets.
Values indicate the fold change in transcript levels in IP6K1/2 double knockout (DKO) cells, or TNP-, SC-919-, or FMP-201300-treated HCT116 cells compared to HCT116 WT cells. The fold change was …
Figure 5 with 1 supplement
Hydrogen deuterium exchange mass spectrometry (HDX-MS) reveals increased flexibility in the β2–β3 strands and αC helix induced by the IP6K1L210V mutation that sensitize the enzyme to FMP-201300.
(a) HDX differences in IP6K1. Time course of deuterium incorporation for a selection of peptides. Raw data can be found in the Supplementary file 1. (b) Overall HDX-MS changes in deuterium …
-
Figure 5—source data 1
Hydrogen deuterium exchange mass spectrometry raw data.
- https://cdn.elifesciences.org/articles/88982/elife-88982-fig5-data1-v1.xlsx
Figure 5—figure supplement 1
Hydrogen deuterium exchange mass spectrometry (HDX-MS) shows FMP-201300 binding to IP6K1L210V leads to decreases that correspond to an allosteric mechanism of action.
Differences in deuterium exchange rates mapped on a model of IP6K1wt (AlphaFold structure prediction Q92551 with ATP and InsP6 from EhIP6KA docked in the active site (PDB: 4O4F)). Peptides that …
Additional files
-
Supplementary file 1
Hit compounds selective for IP6K1L210V.
FMP-201300, highlighted in green, is the most promising compound as it is not displaying any PAINS motifs, has no known inhibitory activities, and is neither redox-active nor cytotoxic. All values are for IP6K1L210V if not otherwise indicated.
- https://cdn.elifesciences.org/articles/88982/elife-88982-supp1-v1.xlsx
-
Supplementary file 2
Cytotoxicity of selected hits indicated by cell survival after 72 hr incubation at 10 µM concentration.
All compounds were measured in independent triplicates and errors represent standard deviation. Redox activity of selected compounds measured via a photometric surrogate assay. Reactions contained 50 mM HEPES pH 7.5, 50 mM NaCl, 200 mM DTT, and 20 µM resazurin, and were incubated for 1 hr at 37°C.
- https://cdn.elifesciences.org/articles/88982/elife-88982-supp2-v1.xlsx
-
Supplementary file 3
Primers used for ligation-independent cloning and site-directed mutagenesis.
- https://cdn.elifesciences.org/articles/88982/elife-88982-supp3-v1.xlsx
-
MDAR checklist
- https://cdn.elifesciences.org/articles/88982/elife-88982-mdarchecklist1-v1.pdf
